THC Limits by Country in Europe: Complete Comparison

THC limits across European countries represent one of the most fragmented aspects of cannabis regulation on the continent. While the EU establishes a baseline of 0.3% THC for industrial hemp under the Common Agricultural Policy, member states apply widely varying THC thresholds across different product categories — hemp cultivation, CBD products for consumer sale, food products, cosmetics, and medical cannabis. These differences create a patchwork regulatory environment that complicates cross-border trade, product development, and compliance planning for companies operating across multiple markets. Understanding THC limits is critical for several stakeholder groups: hemp farmers selecting varieties and managing crop risk, CBD product manufacturers formulating products for multi-market distribution, importers and exporters navigating customs clearance requirements, and medical cannabis companies managing product specifications. The picture is further complicated by the fact that some countries regulate total THC (including THC-A, the acidic precursor), while others measure only delta-9-THC, and analytical methodologies may differ between jurisdictions. This guide provides a comprehensive comparison of THC regulatory limits across European countries as of 2026.

For industrial hemp cultivation, the EU-wide standard of 0.3% THC (measured as delta-9-THC in the flowering tops) took effect in January 2023 under the reformed Common Agricultural Policy. However, Switzerland, which is not an EU member but participates in many European trade frameworks, permits hemp cultivation up to 1.0% THC — the most permissive threshold in Europe. Within the EU, the 0.3% standard applies to CAP eligibility and authorized varieties, but some member states had previously applied stricter limits (notably France, which maintained 0.2% before the EU-wide change) or may apply different measurement methodologies that effectively alter the threshold. The Czech Republic applies the 0.3% limit but has proposed raising it further for certain applications. Italy applies 0.2% as a cultivation limit with a 0.6% tolerance threshold before mandatory crop destruction — a uniquely flexible approach that reduces farmer risk.

For CBD and consumer products containing THC, limits are far less standardized. Austria permits CBD food products with up to 0.3% THC. Belgium sets a strict 0.0% THC for consumer products (effectively zero tolerance). The Czech Republic allows 1.0% THC in CBD products — among the most permissive in Europe. France prohibits any detectable THC in finished CBD products, though enforcement of this near-zero standard has been challenged in courts. Germany applies a THC limit tied to the BfArM reference value of 0.2% for consumer products but treats any product with pharmacological-level THC content as a pharmaceutical requiring authorization. Italy permits consumer CBD products with THC below 0.5% in some interpretations, though enforcement varies by region. The Netherlands treats CBD products with any THC as falling under the Opium Act, though enforcement for trace amounts is minimal. Poland, Slovakia, and the Baltic states generally apply restrictive standards aligned with their controlled substance frameworks. Switzerland permits up to 1.0% THC in consumer products, making it the most accessible market in the region.

Medical cannabis THC limits follow pharmaceutical rather than agricultural or consumer standards. Authorized medical cannabis products in Germany must meet German Pharmacopoeia specifications, which define accepted ranges for THC content based on the specific strain or product rather than imposing a fixed maximum. Common medical cannabis varieties available in European pharmacies range from 1% THC to 25%+ THC depending on the indication and prescription. The Netherlands' Bedrocan program supplies standardized medical cannabis at precisely defined THC levels (e.g., Bedrocan variety at 22% THC, Bediol at 6.3% THC). Italy's medical cannabis program supplies products ranging from 5% to 22% THC through the Military Pharmaceutical Chemical Plant in Florence and through imports. Denmark, Poland, Czech Republic, and other countries with medical cannabis programs similarly regulate THC content through pharmaceutical quality standards rather than fixed limits, ensuring consistency through batch-level testing and certificate of analysis requirements.

For travelers and personal possession, THC limits interact with broader drug policy frameworks. The Netherlands tolerates possession of up to 5 grams of cannabis of any potency. Germany legalized possession of up to 25 grams for personal use in 2024. Portugal decriminalized personal possession of up to 25 grams (for all drugs) since 2001. Spain permits private use and cultivation but not public possession or sale. Most Eastern European countries maintain strict prohibition with no meaningful personal possession thresholds, and THC at any level triggers controlled substance violations. The interaction between product THC levels, possession laws, and cross-border transport creates a multi-dimensional compliance matrix that requires careful analysis for any company or individual operating across European borders.